A high dose of pociredir, Fulcrum Therapeutics’ oral drug candidate for sickle cell disease (SCD), boosted fetal hemoglobin (HbF) levels and reduced red blood cell destruction — thereby easing symptoms of anemia — in a small group of patients with the blood disorder. These are the latest results…